Crucial roles of RSK in cell motility by catalysing serine phosphorylation of EphA2
Citations Over TimeTop 10% of 2015 papers
Abstract
Crosstalk between inflammatory signalling pathways and receptor tyrosine kinases has been revealed as an indicator of cancer malignant progression. In the present study, we focus on EphA2 receptor tyrosine kinase, which is overexpressed in many human cancers. It has been reported that ligand-independent phosphorylation of EphA2 at Ser-897 is induced by Akt. We show that inflammatory cytokines promote RSK-, not Akt-, dependent phosphorylation of EphA2 at Ser-897. In addition, the RSK-EphA2 signalling pathway controls cell migration and invasion of metastatic breast cancer cells. Moreover, Ser-897-phosphorylated EphA2 co-localizes with phosphorylated active form of RSK in various human tumour specimens, and this double positivity is related to poor survival in lung cancer patients, especially those with a smoking history. Taken together, these results indicate that the phosphorylation of EphA2 at Ser-897 is controlled by RSK and the RSK-EphA2 axis might contribute to cell motility and promote tumour malignant progression.
Related Papers
- → The EphA2 Receptor and EphrinA1 Ligand in Solid Tumors: Function and Therapeutic Targeting(2008)297 cited
- → Quantifying the strength of heterointeractions among receptor tyrosine kinases from different subfamilies: Implications for cell signaling(2020)38 cited
- → Functional Oligomerization of the EphA2 Receptor Tyrosine Kinase(2020)1 cited
- Both EphA2 and EphA1 are sufficient in mediating suppression of Erk activity in MEFs(2005)
- EphA_2 and tumor(2008)